Report Adverse Event or Product Quality Complaint US Site Global Site

Prescribing Information
Therapy areas
Disease Education
Resources
Connect

Search Medical Information

Request a field medical follow-up

Home
Disease Education
Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

ACT on COPD
Scientific Resources
Publications
Meet Us

AstraZeneca is committed to the proactive and early identification of patients with COPD, enabling timely initiation of evidence-based disease management. By harnessing the latest scientific advances to uncover the heterogeneity of COPD, we aim to optimize patient outcomes.

Are your patients at risk of a future COPD exacerbation?

See how your state's concentration of at-risk patients with COPD compares nationally1,a

Who was considered at-risk?

Patients with ≥2 moderate exacerbations or ≥1 severe exacerbation(s) in a year.^b

At-risk patients with COPD were grouped based on the relative number of patients in the state/territory compared to other states/territories

^aIQVIA Longitudinal Access and Adjudication Data (LAAD) 2023-2024 US claims data. bModerate exacerbations defined as ER or outpatient visit with COPD diagnosis code that require systemic corticosteroids (defined as oral corticosteroids with at least a 3-days’ supply or a single injection of corticosteroid) and/or prescription for antibiotics, within a ±7-day window from the date of the visit. Severe exacerbations defined as an inpatient hospitalization with: COPD ICD in primary position, or, primary diagnosis of respiratory failure or respiratory-related conditions or sepsis or pneumonia or bronchitis with a COPD ICD in any position.

COPD Exacerbations are often:

Under-reported

In one study, despite meeting criteria of a symptom-based definition,^a 50% of exacerbations were not reported^2,b

Findings from a retrospective cohort study^c of Medicare claims data from ~1.5 M patients with COPD found that, among those with 1 exacerbation (moderate or severe) in year 1, approximately 50% did not receive long-acting maintenance therapy^d during each study year^3,e

^aAn exacerbation was considered unreported if it met the criteria for a symptom-based definition but either were not reported to a healthcare professional and/or did not meet the definition of an HCRU-defined exacerbation.

^bFindings from a prespecified secondary analysis of data from a phase II, 6-month study in 235 patients (US) with COPD receiving an investigational drug.

^cRetrospective cohort study of Medicare FFS claims data in ~1.5 M patients with COPD to quantify the effects of moderate and/or severe exacerbations on future exacerbations and healthcare costs. Patients were ≥40 years of age, with continuous enrollment from 2015 to 2018. Patients with 1 moderate exacerbation at baseline in year 1 (n=318,786), patients with 1 severe exacerbations at baseline in year 1 (n=26,029).

^dICS+LABA, LAMA Mono, Open Triple (ICS+LAMA+LABA), ICS Mono, LABA Mono, or LABA+LAMA.

^eBaseline Year 1, Year 2 and Year 3.

Understanding COPD

Risk Factors
Burden of disease
Consequences of exacerbations
Raise the standard of care

Additional factors that may increase the risk for future exacerbations include:

Increased dyspnea grade^4,a
Frequent productive cough^5,b

Exacerbation history can predict future events

Findings from a retrospective cohort studyc of Medicare claims data from ~1.5 M patients with COPD highlights how exacerbation history predicted the risk for future events.^3,d

Baseline Exacerbations and Risks for Future Events³

^aRetrospective observational cohort study that evaluated risk factors associated with exacerbation frequency in 58,589 patients with COPD identified in the UK Clinical Practice Research Datalink.

^bAnalysis of 7,125 patients from the prospective, observational study, NOVELTY, to describe the relationship between frequent productive cough and disease characteristics, disease burden, and exacerbation risk. Frequent productive cough was defined as cough and sputum production several or most days a week (SGRQ cough and sputum scores ≥3) in the past 3 months.

^cRetrospective cohort study of Medicare FFS claims data in ~1.5 M patients with COPD that quantified the type and frequency of COPD exacerbations over three years by prior exacerbation history.

^dRate of moderate or severe exacerbations expressed as per patient-year.

COPD is a major healthcare burden and a leading cause of death in the US^6,a

~11.7 million people are diagnosed with COPD in the US, representing ~4.6% of the adult population^7,b

Within a 3-yearc period, up to 77% of patients with COPD had ≥1 moderate or severe exacerbation^8-11

The graphic below shows the percentage of patients in: ECLIPSE,8,d UPLIFT,9,e TIOSPIR,11,f and SPIROMICS10,g studies with COPD exacerbations reported over the study period^8-11,h,i

^aCumulative data from 2015-2019. Mortality patterns disrupted by COVID-19 beginning in 2020.

^bData from 2022, adults 18 years and older.

^cRefers to the duration of the clinical and RWE longitudinal studies, not a specific timeframe after diagnosis.

^dECLIPSE was a longitudinal observational study that followed patients over a period of 3 years (patients were recruited from December 2005 through December 2006).

^eUPLIFT was a 4-year randomized, double-blind, placebo-controlled, parallel-group clinical trial investigating an inhaled LAMA medication in patients with moderate to very-severe COPD with patients recruited from January 2003 through March 2004.

^fTIOSPIR was a randomized, double-blind, parallel group, event-driven trial with follow-up of 2-3 years that enrolled patients from May 2010 to April 2011.

^gEvaluation of 1105 patients enrolled between November 2010 and July 2015 with 3 years of exacerbation data from the multicenter, longitudinal SPIROMICS cohort.

^hNot head-to-head.

ⁱBaseline characteristic GOLD stage (patient distribution) - ECLIPSE (N=2138): II (44.2%), III (42.1%); IV (13.7%); UPLIFT (N=5992): II(46%), III (44%), IV (9%); TIOSPIR (N=13591): I (0.2%), II (48.2%), III (40%), IV (10.3%); SPIROMICS (N=1105): I (24.8%), II (44.7%), III (22.6%); IV (7.9%).

Patients with COPD are at risk of lung function decline,^12,13 cardiovascular events,¹⁴ and premature death¹⁵

Hypothetical Disease Progression for a Patient With COPD¹⁶

Figure adapted from Singh D et al. Adv Ther. 2024;41:2151-2167. ¹⁶

Exacerbations can irreversibly reduce lung function

Following an exacerbation, lung function may not recover to pre-exacerbation levels^12,a. In some patients, there was still a loss of lung function 8 weeks following an exacerbation.^12,a

A Post Hoc Analysis of the WISDOM Study

Increased risk of cardiovascular events

A post-hoc analysis of a large randomized control trial was performed to determine whether the risk for CV eventsb increases after a moderate/severe exacerbation in patients with COPD and existing or risk factors for cardiovascular disease.^14,c Compared with pre-exacerbation baseline periods, there was an increased risk of CV eventsb which persisted for up to a year after an exacerbation. In the first 30 days following a COPD hospitalization, there was an ~10x increased risk of a CV eventb compared to pre exacerbation baseline periods.¹⁴

In Patients With COPD and Existing or Risk Factors for CVD:

~10x Compared with pre-exacerbation baseline periods, the risk of a CV event increased 10x within 30 days of a COPD hospitalization¹⁴

Exacerbations increased mortality risk

~25% of patients died within 1 year after a COPD hospitalization^15,d 

In a UK population-based study of ~100,000 patients with COPD,^e the odds of death increased by 80% in patients who had 2 moderate exacerbations in the prior year compared to those who had none.¹⁷

^aA post-hoc analysis of the WISDOM study in 360 patients with moderate-to-very-severe COPD to characterize lung function before, during, and after a moderate/severe and severe COPD exacerbation.

^bCV events comprised a composite outcome of CV death, MI, stroke, unstable angina, and transient ischemic attack.

^cPost-hoc analysis of the SUMMIT trial (n=16,485).

^dBased on Medicare standard analytical and denominator files (reporting period: 2008-2014) from ~1.3 M patients (US) ≥65 years who were admitted to acute care hospitals with a principal diagnosis of COPD or a principal diagnosis of acute respiratory failure combined with a secondary diagnosis of COPD with acute exacerbation. Patients with in-hospital death, less than 1 year of enrollment in Medicare FFS in the absence of death, or those transferred to another acute care facility or discharged against medical advice were excluded.

^eData from the UK Clinical Practice Research Datalink (population-based study) of ~100,000 patients with COPD investigating the effect of baseline AECOPD on future events with a follow-up of up to 10 years. Moderate exacerbations were defined as those managed outside the hospital and severe as those requiring hospitalization. Results based on adjusted odds ratios (OR) in the case-control study (adjusted for age, sex, smoking status, body mass index, comorbidities, and FEV₁% predicted) for comparison of patients who had moderate exacerbation(s) in the 12 months prior vs those who had none. The following results reported as number of moderate exacerbations in the 12 months prior: Odds Ratio (95% CI): 1: 1.18 (0.83-1.67); 2: 1.80 (1.19-2.70); 3: 1.98 (1.13-3.49); 4: 1.00 (0.53-1.86); ≥5: 2.33 (1.45-3.76); No AECOPD: (OR=1.0).

The time to act is now

A more proactive disease management approach can help improve outcomes for patients with COPD.¹⁸

1. Identify at Risk Patients^19,20,a

Symptomatic patients regardless of a recent history of exacerbations⁴:

Increased dyspnea (mMRC ≥2)^18,b
Frequent productive cough^5,c

Patients with a recent history of exacerbations³

2. Optimize Management^18,20

Prevent exacerbations, CV complications, and decrease risk of mortality²⁰:

Non-pharmacological interventions (eg, smoking cessation, pulmonary rehab, vaccination)¹⁸
Appropriate initiation and escalation of pharmacological treatments¹⁸

3. Timing of Care

Help improve outcomes with a more proactive disease management approach¹⁸:

Early follow-up after hospital discharge is recommended to optimize treatment in accordance with evidence-based recommendations¹⁸

^aIncluding patients at-risk of cardiopulmonary events.

^bGOLD considers mMRC ≥2 (equivalent to MRC ≥3) a threshold for separating “less breathlessness” from “more breathlessness.”

^cDefined as cough and sputum production several or most days a week (SGRQ cough and sputum scores ≥3) in the past 3 months.

How to ACT on COPD

What can you do to help prevent your patient's next exacerbation?

Has the patient experienced a recent change in symptoms?¹⁸

Dyspnea

Sputum purulence or volume

Cough

Fatigue

Signs of hypercapnia  

Evaluate opportunities to optimize management

Lung function, symptom burden, and exacerbation history should be used as a guide to optimize COPD management¹⁸

Smoking cessation

Vaccinations

Pharmacologic therapy

Physical activity

Pulmonary rehabilitation

Adjust pharmacological treatment, as recommended

Follow up of patients with COPD¹⁸

Regular follow-up to optimize pharmacological and non-pharmacological intervention.  Any change in treatment requires a subsequent review of the clinical response.¹⁸

Transforming COPD Care

This checklist is based on the GOLD Report and can serve as a resource to help standardize patient discharge following a COPD hospitalization

View the Transition of Care Discharge  Checklist

A resource for pharmacists to help identify COPD exacerbation(s) in at-risk patients with COPD and provide counseling guidance 

View Pharmacist Assessment Checklist

The CONQUEST Infographic describes quality standards for the identification and management of patients with COPD at risk of exacerbations or acute respiratory events

View CONQUEST Infographic

GOLD Report Combined Initial COPD Assessment & Management

This content includes the GOLD Report figures for the ABE Assessment Tool, Initial Pharmacological Treatment, Follow-up Pharmacological Treatment, and Management of Patients Currently on LABA + ICS

View the Resource

AECOPD: acute exacerbations of chronic obstructive pulmonary disease

COPD: chronic obstructive pulmonary disease

CV: cardiovascular

CVD: cardiovascular disease

FEV1: forced expiratory volume in 1 second

FFS: fee for service

ER: emergency room

HCRU: healthcare resource utilization

ICD: International Classification of Diseases

ICS: inhaled corticosteroid(s)

LABAlong-acting β2-agonist

LAMA: long-acting muscarinic antagonis

tMI: myocardial infarction

MRC: Medical Research Council

mMRC: modified Medical Research Council

OR: odds ratio

SGRQ: St. George's Respiratory Questionnaire

RWE: real-world evidence

UK: United Kingdom

US: United States

1. IQVIA Longitudinal Access and Adjudication Data (LAAD) US claims data for the reporting period [4th Quarter 2023 to 4th Quarter 2024 (Date Retrieved: March 25, 2025)].

2. Leidy NK, Murray LT, Jones P, et al. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(3):316-325.

3. Sethi S, Make BJ, Robinson SB, et al. Relationship of COPD exacerbation severity and frequency on risks for future events and economic burden in the Medicare fee-for-service population. Int J Chron Obstruct Pulmon Dis. 2022;17:593-608. Published 2022 Mar 20. doi:10.2147/COPD.S350248

4. Müllerová H, Shukla A, Hawkins A, et al. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171. https://doi.org/10.1136/bmjopen-2014-006171

5. Hughes R, Rapsomaniki E, Janson C, et al. Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study [supplementary data]. Respir Med. 2022;200:106921.

6. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829-1830. doi:10.1001/jama.2021.5469

7. American Lung Association. COPD Trends Brief: Prevalence. American Lung Association Website. https://www.lung.org/research/trends-in-lung-disease/copd-trends-brief/copd-prevalence

8. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138. https://doi.org/10.1056/NEJMoa0909883

9. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554. https://doi.org/10.1056/NEJMoa0805800

10. Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in COPD: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619-626.

11. Calverley PM, Tetzlaff K, Dusser D, et al. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. Int J Chron Obstruct Pulmon Dis. 2017;12:3391-3405. doi: 10.2147/COPD.S145814

12. Watz H, Tetzlaff K, Magnussen H, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018;19(1):251. https://doi.org/0.1186/s12931-018-0944-3

13. Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):324-330. https://doi.org/10.1164/rccm.201605-1014OC

14. Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51-57.

15. Lindenauer PK, Dharmarajan K, Qin L, et al. Risk trajectories of readmission and death in the first year after hospitalization for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(8):1009-1017. https://doi.org/10.1164/rccm.201709-1852oc

16. Singh D, Han MK, Hawkins NM, et al. Implications of cardiopulmonary risk for the management of COPD: a narrative review. Adv Ther. 2024;41:2151-2167. https://doi.org/10.1007/s12325-024-02855-4

17. Rothnie KJ, Müllerová H, Smeeth L, et al. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464-471. https://doi.org/10.1164/rccm.201710-2029OC

18. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report). GOLD website. https://goldcopd.org/2025-gold-report/

19. Singh D, Holmes S, Adams C, et al. Overcoming therapeutic inertia to reduce the risk of COPD exacerbations: four action points for healthcare professionals. Int J Chron Obstruct Pulmon Dis. 2021;16:3009-3016.

20. Pullen R, Miravitlles M, Sharma A, et al. CONQUEST quality standards: for the collaboration on quality improvement initiative for achieving excellence in standards of COPD care. Int J Chron Obstruct Pulmon Dis. 2021;16:2301-2322. https://doi.org/10.2147/COPD.S313498

Scientific Resources

This section offers scientific resources related to COPD, including videos, slide decks, and infographics. Our AstraZeneca Medical team has created this content as an information service for healthcare professionals. Updates are made as new content becomes available. This section also includes links to resources provided by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the COPD Foundation.

Videos

An Animated Exploration of the PRIMUS Study

This video is a brief overview of the PRIMUS study in a whiteboard-style animation   

Navigating Inhaler Choice and Training Video

This video discusses navigating the complexities of inhaler choice and training   

Physical Activity Roundtable Video

This video discusses reduced activity in patients with COPD and the impact on COPD outcomes, stimulating patient engagement to improve management of COPD, and practical approaches to increasing physical activity

Slide Decks

PRIMUS Study Overview Slide deck

This presentation provides an overview of the analysis of triple therapy initiation following a disease exacerbation among patients with chronic obstructive pulmonary disease (PRIMUS)

View Slide Deck

COPD Pathophysiology and Management of Disease-GOLD 2025

This presentation reviews the pathophysiology of COPD and the updated GOLD 2025 Report

View Slide Deck

The Importance of Device Choice in COPD Treatment

This presentation reviews the importance of inhaler device selection, types of devices available, and the importance of training

View Slide Deck

Exploring the Dual Role of IL-33 in COPD Pathogenesis

This presentation provides an overview of the burden of COPD, defines the role of IL-33 as an upstream alarmin, explores the dual effects of IL-33 through reduced and oxidized forms, and examines how dysregulation of IL-33 signaling pathways is associated with biological mechanisms of COPD.

View Slide Deck

Infographics

Achieving Health Equity Through Race-Neutral Spirometry

2-page infographic illustrates the evolution of race-based spirometry and its implications for COPD diagnosis across diverse patient populations

View the Infographic

COPD Transition of Care Discharge Checklist

Transition of Care Discharge Checklist for patients with COPD discharged after COPD hospitalization

View the Infographic

Pharmacists: Advocating for at-risk patients with COPD

A resource for pharmacists to help identify COPD exacerbation(s) in at-risk patients with COPD and provide counseling guidance

View the Infographic

CONQUEST Infographic

The CONQUEST Infographic describes quality standards for the identification and management of patients with COPD at risk of exacerbations or acute respiratory events

View the Infographic

Achieving Health Equity Through Race-Neutral Spirometry

This content includes the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report figures for the ABE Assessment Tool, Initial Pharmacological Treatment, Follow-up Pharmacological Treatment, and Management of Patients Currently on LABA + ICS

View the Infographic

External Resources

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) works with healthcare professionals and public health officials around the world to raise awareness of Chronic Obstructive Pulmonary Disease (COPD) and to improve prevention and treatment of this lung disease.

Go to goldcopd.org

The COPD Foundation is a patient-centred organization committed to preventing COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease, and to seeking cures while improving lives and advocating for all affected.

Go to COPDfoundation.org

AvoMD is a software platform that translates clinical evidence, including the GOLD Report, into the workflow at the point of care, and is available in the electronic health record or as a standalone web/mobile application.

Go to AvoMD.io GOLD workflow

Publications

This section provides links to AstraZeneca publications that present data and real-world evidence from studies on COPD.

Cardiopulmonary Risk Review Paper

Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review

Access Article

PRIMUS

Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation

Access Article

CONQUEST 1

CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care

Access Article

CONQUEST 2

CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients

Access Article

EXACOS-CV US Study

Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study 

Access Article

Meet Us

Are you interested in learning more about the unmet need in COPD care for patients? Would you like to meet with someone from the AstraZeneca Medical team to learn more about AstraZeneca’s ambition in transforming care in COPD? Use the link below to connect with a Medical Science Liaison in your region. You can also connect with us at one of the following congresses.

Connect with an MSL

Connect with a Medical Science Liaison for your region latest information from AstraZeneca.

Find an MSL

Meet Us at a Congress

Michigan College of Emergency Physicians (MCEP)

Boyne Falls, MI
January 23 - 26, 2025

Kentucky Academy of Family Physicians (KAFP)

Louisville, KY
February 7 - 9, 2025

California Academy of Physician Associates (CAPA)

Sonoma, CA
February 22 - 23, 2025

American Pharmacists Association (APhA)

Nashville, TN
March 21 - 24, 2025

Florida Academy of Family Physicians (FAFP)

Orlando, FL
April 4 - 6, 2025

Nurse Practitioner Associates for Continuing Education (NPACE)

Chicago, IL
April 7 - 9, 2025

Wisconsin Nurses Association (WNA)

Madison, WI
April 10 - 11, 2025

Pri-Med West

Anaheim, CA
May 8 - 10, 2025

American Academy of Physician Assistants (AAPA)

Denver, CO
May 16 - 20, 2025

Pri-Med West

San Francisco, CA
May 16 - 21, 2025

American Association of Nurse Practitioners (AANP)

San Diego, CA
June 17 - 22, 2025

Association of Pulmonary Advanced Practice Providers (APAPP)

Nashville, TN
June 26 - 28, 2025

American Association for Respiratory Care (AARC)

Fort Lauderdale, FL
July 12 - 14, 2025

Utah Physician Assistants & Nurse Practitioners Conference

Snowbird, UT
July 30 - August 1, 2025

Eastern Pulmonary Conference (EPC)

Palm Beach, FL
September 4 - 7, 2025

California Academy of Family Physicians (CAFP)

San Diego, CA
September 5 - 7, 2025

American Academy of Family Physicians - Family Medicine Experience (AAFP FMX)

Anaheim, CA
October 5 - 9, 2025

American College of Chest Physicians (CHEST)

Chicago, IL
October 19 - 22, 2025

Pri-Med East

Boston, MA
October 22 - 24, 2025

GOLD International COPD Conference

Philadelphia, PA
November 12 - 13, 2025

Texas Academy of Family Physicians (TAFP)

Addison, TX
November 14 - 16, 2025

Florida Academy of Family Physicians (FAFP)

Amelia Island, FL
December 5 - 7, 2025

American Society of Health-System Pharmacists (ASHP)

Las Vegas, NV
December 7 - 11, 2025

US-104418, US-98679 Last Updated 9/25

Consumer Health Data  Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person

What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.

I am not a healthcare professional practicing in the United States

Request a field medical follow-up

Chronic Obstructive Pulmonary Disease

AstraZeneca is committed to the proactive and early identification of patients with COPD, enabling timely initiation of evidence-based disease management. By harnessing the latest scientific advances to uncover the heterogeneity of COPD, we aim to optimize patient outcomes.

Under-reported

In one study, despite meeting criteria of a symptom-based definition,a 50% of exacerbations were not reported2,b

Findings from a retrospective cohort studyc of Medicare claims data from ~1.5 M patients with COPD found that, among those with 1 exacerbation (moderate or severe) in year 1, approximately 50% did not receive long-acting maintenance therapyd during each study year3,e

1. Identify at Risk Patients19,20,a

2. Optimize Management18,20

3. Timing of Care

What can you do to help prevent your patient's next exacerbation?

Has the patient experienced a recent change in symptoms?18 Dyspnea Sputum purulence or volume Cough Fatigue Signs of hypercapnia

Evaluate opportunities to optimize management

Lung function, symptom burden, and exacerbation history should be used as a guide to optimize COPD management18 Smoking cessation Vaccinations Pharmacologic therapy Physical activity Pulmonary rehabilitation

Adjust pharmacological treatment, as recommended

Follow up of patients with COPD18 Regular follow-up to optimize pharmacological and non-pharmacological intervention. Any change in treatment requires a subsequent review of the clinical response.18

Abbreviations

References

An Animated Exploration of the PRIMUS Study

Navigating Inhaler Choice and Training Video

Physical Activity Roundtable Video

This presentation provides an overview of the analysis of triple therapy initiation following a disease exacerbation among patients with chronic obstructive pulmonary disease (PRIMUS)

This presentation reviews the pathophysiology of COPD and the updated GOLD 2025 Report

This presentation reviews the importance of inhaler device selection, types of devices available, and the importance of training

This presentation provides an overview of the burden of COPD, defines the role of IL-33 as an upstream alarmin, explores the dual effects of IL-33 through reduced and oxidized forms, and examines how dysregulation of IL-33 signaling pathways is associated with biological mechanisms of COPD.

2-page infographic illustrates the evolution of race-based spirometry and its implications for COPD diagnosis across diverse patient populations

Transition of Care Discharge Checklist for patients with COPD discharged after COPD hospitalization

A resource for pharmacists to help identify COPD exacerbation(s) in at-risk patients with COPD and provide counseling guidance

The CONQUEST Infographic describes quality standards for the identification and management of patients with COPD at risk of exacerbations or acute respiratory events

This content includes the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report figures for the ABE Assessment Tool, Initial Pharmacological Treatment, Follow-up Pharmacological Treatment, and Management of Patients Currently on LABA + ICS

External Resources

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) works with healthcare professionals and public health officials around the world to raise awareness of Chronic Obstructive Pulmonary Disease (COPD) and to improve prevention and treatment of this lung disease.

The COPD Foundation is a patient-centred organization committed to preventing COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease, and to seeking cures while improving lives and advocating for all affected.

AvoMD is a software platform that translates clinical evidence, including the GOLD Report, into the workflow at the point of care, and is available in the electronic health record or as a standalone web/mobile application.

Michigan College of Emergency Physicians (MCEP)

Boyne Falls, MI January 23 - 26, 2025

Kentucky Academy of Family Physicians (KAFP)

Louisville, KY February 7 - 9, 2025

California Academy of Physician Associates (CAPA)

Sonoma, CA February 22 - 23, 2025

American Pharmacists Association (APhA)

Nashville, TN March 21 - 24, 2025

Florida Academy of Family Physicians (FAFP)

Orlando, FL April 4 - 6, 2025

Nurse Practitioner Associates for Continuing Education (NPACE)

Chicago, IL April 7 - 9, 2025

Wisconsin Nurses Association (WNA)

Madison, WI April 10 - 11, 2025

Pri-Med West

Anaheim, CA May 8 - 10, 2025

American Academy of Physician Assistants (AAPA)

Denver, CO May 16 - 20, 2025

Pri-Med West

San Francisco, CA May 16 - 21, 2025

American Association of Nurse Practitioners (AANP)

San Diego, CA June 17 - 22, 2025

Association of Pulmonary Advanced Practice Providers (APAPP)

Nashville, TN June 26 - 28, 2025

American Association for Respiratory Care (AARC)

Fort Lauderdale, FL July 12 - 14, 2025

Utah Physician Assistants & Nurse Practitioners Conference

Snowbird, UT July 30 - August 1, 2025

Eastern Pulmonary Conference (EPC)

Palm Beach, FL September 4 - 7, 2025

California Academy of Family Physicians (CAFP)

San Diego, CA September 5 - 7, 2025

American Academy of Family Physicians - Family Medicine Experience (AAFP FMX)

Anaheim, CA October 5 - 9, 2025

American College of Chest Physicians (CHEST)

Chicago, IL October 19 - 22, 2025

Pri-Med East

Boston, MA October 22 - 24, 2025

GOLD International COPD Conference

Philadelphia, PA November 12 - 13, 2025

Texas Academy of Family Physicians (TAFP)

Addison, TX November 14 - 16, 2025

Florida Academy of Family Physicians (FAFP)

Amelia Island, FL December 5 - 7, 2025

American Society of Health-System Pharmacists (ASHP)

Las Vegas, NV December 7 - 11, 2025

Welcome to AstraZeneca Medical Information

In one study, despite meeting criteria of a symptom-based definition,^a 50% of exacerbations were not reported^2,b

Findings from a retrospective cohort study^c of Medicare claims data from ~1.5 M patients with COPD found that, among those with 1 exacerbation (moderate or severe) in year 1, approximately 50% did not receive long-acting maintenance therapy^d during each study year^3,e

1. Identify at Risk Patients^19,20,a

2. Optimize Management^18,20

Has the patient experienced a recent change in symptoms?¹⁸

Dyspnea

Sputum purulence or volume

Cough

Fatigue

Signs of hypercapnia  

Lung function, symptom burden, and exacerbation history should be used as a guide to optimize COPD management¹⁸

Smoking cessation

Vaccinations

Pharmacologic therapy

Physical activity

Pulmonary rehabilitation

Follow up of patients with COPD¹⁸

Regular follow-up to optimize pharmacological and non-pharmacological intervention.  Any change in treatment requires a subsequent review of the clinical response.¹⁸

Boyne Falls, MI
January 23 - 26, 2025

Louisville, KY
February 7 - 9, 2025

Sonoma, CA
February 22 - 23, 2025

Nashville, TN
March 21 - 24, 2025

Orlando, FL
April 4 - 6, 2025

Chicago, IL
April 7 - 9, 2025

Madison, WI
April 10 - 11, 2025

Anaheim, CA
May 8 - 10, 2025

Denver, CO
May 16 - 20, 2025

San Francisco, CA
May 16 - 21, 2025

San Diego, CA
June 17 - 22, 2025

Nashville, TN
June 26 - 28, 2025

Fort Lauderdale, FL
July 12 - 14, 2025

Snowbird, UT
July 30 - August 1, 2025

Palm Beach, FL
September 4 - 7, 2025

San Diego, CA
September 5 - 7, 2025

Anaheim, CA
October 5 - 9, 2025

Chicago, IL
October 19 - 22, 2025

Boston, MA
October 22 - 24, 2025

Philadelphia, PA
November 12 - 13, 2025

Addison, TX
November 14 - 16, 2025

Amelia Island, FL
December 5 - 7, 2025

Las Vegas, NV
December 7 - 11, 2025